Vaccines

Despite public health recommendations, a new study has found that too many adolescents and young adults in the United States are failing to complete the full vaccination course for HPV.

Following recent reports that England has seen more measles cases so far in 2018 than in all of 2017, health officials are combating outbreaks of the virus with vaccination clinics.

Researchers have found that a vaccine for Junin virus, a South American hemorrhagic fever virus, protects against another virus in the same family, opening up the possibility for universal vaccines for virus families.

In case you missed them, we've compiled the top 5 articles from this past week.

A phase 2 trial of an experimental universal flu vaccine is moving forward with sponsorship from The National Institute of Allergy and Infectious Diseases.

Novavax announces that enrollment in phase 3 Prepare trial has reached approximately 4,600 participants, of whom, at least 3,000 have received the RSV F vaccine.

If clinical development progresses, the PaxVax vaccine could potentially become the first vaccine approved by the FDA for the prevention of chikungunya.

A recent study has found that a single-dose of Merck's Ebola vaccine delivers antibodies that can last for 1 to 2 years.

If this indication is approved, physicians will be able to reserve the vaccine for young children to protect them against the 2019-2020 flu season.

Following outbreaks of measles and yellow fever in parts of Central America, South America, and the Caribbean, PAHO is leading the 16th annual Vaccination Week in the Americas in an effort to vaccinate 70 million individuals against several diseases.

This is the first Breakthrough Therapy designation for a MenB vaccine to help protect children as young as 1 year of age.

Stay up-to-date on the latest infectious disease news by checking out our top 5 articles of the week.

New strains of the mumps virus are not to blame for the recent resurgence of cases, say researchers in a new study, instead pinning the recent outbreaks on declining protective effects of the mumps vaccine over time.

Representatives from Novavax, Inc., an American-based biotechnology company, presented data at the recent World Vaccine Congress in Washington, DC, on their vaccines under development for the flu and RSV.

In case you missed them, we've compiled the top five infectious disease articles from this past week.

Investigators set out to find out why pertussis rates in the United States have been rising steadily despite the availability of a vaccine.

Health officials around the United States are still recommending the flu shot for late-season protection against the second wave of flu caused by influenza B.

Health officials are in the process of investigating a mumps outbreak that has sprung up among attendees of Mexican dance events in Delaware.

These recommendations come on the heels of a review of the vaccine by the WHO’s Strategic Advisory Group of Experts on Immunization in October 2017.

Marin H. Kollef, MD, discusses new therapies in development for the treatment of Pseudomonas infections.

In case you missed them, we've compiled the top 5 articles from this past week.

While a new study has found that the HPV vaccination rate has more than tripled among young men in the United States, rates for both males and females are still well below public health targets.

With influenza B making a late-season rise, health officials are warning that B viruses may cause a second wave of flu this season, while the FDA is backing some alternatives to egg-based flu vaccines.

As an outbreak of Lassa fever in Nigeria continues to spread, the Coalition for Epidemic Preparedness Innovations is working with Themis Bioscience to develop a vaccine to protect against the virus.

AIDS researcher Robert Redfield, MD, has officially been named the new director of the CDC.